Share This Article

Facebook LinkedIn
Twitter Reddit
Print Email
Pinterest Gmail
Yahoo
Money Morning
×
  • Invest
    • Best Stocks to Buy
    • Stock Forecasts
    • Stocks to Sell Now
    • Stock Market Predictions
    • Technology Stocks
    • Best REITs to Buy Now
    • IPO Stocks
    • Penny Stocks
    • Dividend Stocks
    • Cryptocurrencies
    • Cannabis Investing
    • Angel Investing
  • Trade
    • How to Trade Options
    • Best Trades to Make Now
    • Options Trading Strategies
    • Weekly Trade Recommendations
  • Retire
    • Income Investing Guide
    • Retirement Articles
  • More
    • Money Morning LIVE
    • Special Investing Reports
    • Our ELetters
    • Our Premium Services
    • Videos
    • Meet Our Experts
    • Profit Academy
Login My Member Benefits Archives Research Your Team About Us FAQ
  • Invest
    • Best Stocks to Buy
    • Stock Forecasts
    • Stocks to Sell Now
    • Stock Market Predictions
    • Technology Stocks
    • Best REITs to Buy Now
    • IPO Stocks
    • Penny Stocks
    • Dividend Stocks
    • Cryptocurrencies
    • Cannabis Investing
    • Angel Investing
    ×
  • Trade
    • How to Trade Options
    • Best Trades to Make Now
    • Options Trading Strategies
    • Weekly Trade Recommendations
    ×
  • Retire
    • Income Investing Guide
    • Retirement Articles
    ×
  • More
    • Money Morning LIVE
    • Special Investing Reports
    • Our ELetters
    • Our Premium Services
    • Videos
    • Meet Our Experts
    • Profit Academy
    ×
  • Subscribe
Enter stock ticker or keyword
×
5 Ways to Beat the Fed (and Crush Inflation)

Email this Article

Send with mail | ahoo instead.
Required Needs to be a valid email
Required Needs to be a valid email
Three Biotech Stocks Poised to Break Out
https://moneymorning.com/?p=1114121
Required Please enter the correct value.
Twitter
Stocks: BIIB, GILD, SUPN

Three Biotech Stocks Poised to Break Out

By Money Morning Staff Reports, Money Morning • August 22, 2019

View Comments

Start the conversation

Comment on This Story Click here to cancel reply.

Or to contact Money Morning Customer Service, click here.

Your email address will not be published. Required fields are marked *

Some HTML is OK

With recession indicators flashing, investors are wondering if this is the end of an historic bull market. But there are still market-beating stocks out there - in fact, one of our picks is expecting 103% growth.

And that brings us to the biotech industry. There are some big biotech stocks to own right now that could deliver triple-digit upside in less than 12 months.

Whether or not the markets rise or fall, medical patients around the world require pain-relieving and life-saving medication to ensure a healthy and productive future.

We're not talking about companies that make aspirin or joint ointments. We're talking about the biopharmaceutical companies working on nerve and anti-seizure medications and treating severe conditions like HIV, multiple sclerosis (MS), and other inflammatory diseases inflicting millions around the globe.

To find the top biotech stocks to buy, we use the Money Morning Stock VQScore™. This propriety stock screening system tracks 1,500 companies and assigns each of them a score based on a proprietary mix of fundamental and technical figures.

Did You Catch This? Serial entrepreneur Neil Patel reveals what it takes to become the world's next angel investor. Click here to watch...

The score is based on a range of 1 to 4.9. The higher the score, the more likely the stock is poised for a massive breakout. Today, we present the three best biotech stocks to buy based on their VQScore.

As a bonus, all three have a remarkable drug pipeline that will net them massive profits. And our top stock has upside of more than 100% in the next few months.

Best Biotech Stocks to Own, No. 3

Biogen Inc. (NASDAQ: BIIB) is a biotech giant that fell on tough times over the last few years. Shares have dropped by nearly 50% from their 2015 high of $475. A large chunk of that downturn came in March 2019, when Biogen announced the failure of an Alzheimer's trial. As a result, many investors have walked away and left this iconic pharmaceutical giant lying on the mat.

However, the company has an inside track on the growing demand for biosimilar products. And it remains a leader in the treatment of MS and spinal muscular atrophy.

Another thing we like: Institutional traders and insiders have boosted their stakes in the company. For example, hedge fund Sarissa Capital Management purchased $27.2 million in shares during the second quarter. Meanwhile, CEO Michel Vounasos purchased $1 million in company stock on May 1.

As we know, insider buying by executives is an important signal that things could be turning around at a company. Who better to put their money where their mouth is than the people in the executive suite?

The company has a perfect VQScore of 4.9. That figure signals a major breakout for Biogen stock is coming in the weeks or months ahead. Right now, we set a price target of $300.

That represents an upside of 29.6% from today's price. But our next biotech stock promises nearly double that gain...

Best Biotech Stocks to Own, No. 2

A weak second-quarter earnings report has dragged on shares of Gilead Sciences Inc. (NASDAQ: GILD). That said, there are four reasons why investors should buy the stock today.

First, the company's HIV drug Biktarvy had strong sales in this down quarter. Overall, the company's management appears very excited about the sales potential of this treatment moving forward. That possible growth complements the firm's booming business for hepatitis C treatments.

Second, the company has a robust pipeline of drugs poised for launch in 2020. This list includes a new HIV treatment called Descovy, and Filgitnib, a treatment for Crohn's disease and arthritis.

Third, the company just deepened its relationship with drugmaker Galapagos NV in July by purchasing another 22% of the firm. The 10-year deal will target new advanced treatments for rheumatoid arthritis, inflammatory bowel disease, and other inflammatory diseases.

And finally, the top reason to love Gilead stock, it has a perfect VQScore of 4.9. Any stock with a 4.9 represents a "Buy" and signals a big rally in the future.

Gilead has a price target of $91, which calls for an upside of 44% from today's current level.

But, now, here's our 103% gainer...

Best Biotech Stocks to Own, No. 1

Join the conversation. Click here to jump to comments…

Login
guest
guest
1 Comment
Oldest
Newest Most Voted
Inline Feedbacks
View all comments
charles c youngmd
charles c youngmd
3 years ago

good info.

0
Reply
LIVE
Visit Money Morning Live


Latest News

January 19, 2023 • By Money Morning Stock Research Team

These Stocks Could Go To $0

January 9, 2023 • By Money Morning Stock Research Team

The Government Is Pouring $391 Billion Into These Stocks - Buy Now

December 27, 2022 • By Money Morning Staff Reports

6 IPOs in 2023 You Can’t Afford to Miss
Trending Stories
ABOUT MONEY MORNING

Money Morning gives you access to a team of market experts with more than 250 years of combined investing experience – for free. Our experts – who have appeared on FOXBusiness, CNBC, NPR, and BloombergTV – deliver daily investing tips and stock picks, provide analysis with actions to take, and answer your biggest market questions. Our goal is to help our millions of e-newsletter subscribers and Moneymorning.com visitors become smarter, more confident investors.

QUICK LINKS
About Us COVID-19 Announcements How Money Morning Works FAQs Contact Us Search Article Archive Forgot Username/Password Archives Profit Academy Research Your Team Videos Text Messaging Terms of Use
FREE NEWSLETTERS
Total Wealth Research Power Profit Trades Profit Takeover This Is VWAP Penny Hawk Trading Today Midday Momentum Pump Up the Close
PREMIUM SERVICES
Money Map Press Home Money Map Report Fast Fortune Club Weekly Cash Clock Night Trader Microcurrency Trader Hyperdrive Portfolio Rocket Wealth Initiative Extreme Profit Hunters Profit Revolution Warlock's World Penny Nation Quantum Data Profits Live Trading Alliance Trade The Close Inside Money Trader Expiration Trader Vega Burst Trader Flashpoint Trader Darknet Hyper Momentum Trader

© 2023 Money Morning All Rights Reserved. Protected by copyright of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including the world wide web), of content from this webpage, in whole or in part, is strictly prohibited without the express written permission of Money Morning.

Address: 1125 N Charles St. | Baltimore, MD, 21201 | USA | Phone: 888.384.8339 | Disclaimer | Sitemap | Privacy Policy | Whitelist Us | Do Not Sell My Info

wpDiscuz